Allworth Financial’s Atossa Therapeutics ATOS Stock Holding History

Allworth Financial’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$242	Sell	46 -1	-2%	-$6	﹤0.01%	4890
2025 Q4	$415	Hold	47	–	–	﹤0.01%	4569
2025 Q3	$609	Hold	47	–	–	﹤0.01%	4384
2025 Q2	$583	Hold	47	–	–	﹤0.01%	4096
2025 Q1	$515	Hold	47	–	–	﹤0.01%	3666
2024 Q4	$673	Hold	47	–	–	﹤0.01%	3523
2024 Q3	$1.07K	Hold	47	–	–	﹤0.01%	3195
2024 Q2	$941	Hold	47	–	–	﹤0.01%	3182
2024 Q1	$1.26K	Hold	47	–	–	﹤0.01%	3001
2023 Q4	$618	Hold	47	–	–	﹤0.01%	3081
2023 Q3	$518	Hold	47	–	–	﹤0.01%	3033
2023 Q2	$885	Hold	47	–	–	﹤0.01%	2766
2023 Q1	$509	Hold	47	–	–	﹤0.01%	2836
2022 Q4	$371	Hold	47	–	–	﹤0.01%	2697
2022 Q3	$1K	Hold	47	–	–	﹤0.01%	2305
2022 Q2	$1K	Hold	47	–	–	﹤0.01%	2085
2022 Q1	$1K	Hold	47	–	–	﹤0.01%	1875
2021 Q4	$1K	Hold	47	–	–	﹤0.01%	1784
2021 Q3	$2K	Hold	47	–	–	﹤0.01%	1656
2021 Q2	$4K	Hold	47	–	–	﹤0.01%	1239
2021 Q1	$1K	Buy	+47	New	+$1.72K	﹤0.01%	1366

Other funds holding ATOS

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allworth Financial's ATOS Position: Q1 2026 in Review

Allworth Financial reduced its Atossa Therapeutics (ATOS) stake by 2.1% in Q1 2026, selling an estimated $6 and leaving 46 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #4890.

Allworth Financial first reported a position in ATOS in Q1 2021 and has held it in 21 quarters since. The position peaked at $4K in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Allworth Financial held 46 shares of Atossa Therapeutics worth $242 as of Q1 2026.
Allworth Financial sold 1 Atossa Therapeutics share in Q1 2026, an estimated $6.
Atossa Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4890 holding.
Allworth Financial first reported a position in Atossa Therapeutics in Q1 2021 and has held it in 21 quarters since.
Allworth Financial's Atossa Therapeutics position peaked at $4K in Q2 2021.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.